Valion Bio VBIO
NASDAQ VBIO
$0.96 -0.16 (-14.29%)
At close: Oct 22, 2026 · 4:00 PM EDT

Valion Bio (VBIO) Debt Ratio (2022)

Updated

Analysis

Valion Bio (VBIO) Debt Ratio (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 0.39
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 0.23
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 0.52
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 0.42
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 0.08
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 0.28
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 0.60
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 0.53
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 0.31
10 Valion Bio 129,792.00 -19.31 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 0.08
API Access

Valion Bio Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=VBIO&period=max&api_key=YOUR_API_KEY